Relay Therapeutics (RLAY) Amortizatization of Intangibles (2019 - 2026)
Relay Therapeutics (RLAY) reported Amortizatization of Intangibles of $782000.0 for Q1 2026, down 51.03% year-over-year from $1.6 million in Q1 2025, and down 8.75% on a QoQ basis from $857000.0 in Q4 2025.
Relay Therapeutics (RLAY) has 8 years of Amortizatization of Intangibles data on file, last reported at $782000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 51.03% year-over-year to $782000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 59.66% YoY) and the FY2025 annual result came in at $4.9 million, down 59.81% from the prior year.
- Amortizatization of Intangibles slipped to $782000.0 in Q1 2026 per RLAY's latest filing, from $857000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $3.7 million in Q4 2023 and bottomed at -$681000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $1.6 million (2025), against an average of $1.6 million.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles tumbled 345.1%; it then jumped 945.88% in 2023.
- Tracing RLAY's Amortizatization of Intangibles over 5 years: stood at $385000.0 in 2022, then jumped by 852.99% to $3.7 million in 2023, then sank by 40.56% to $2.2 million in 2024, then plunged by 60.71% to $857000.0 in 2025, then declined by 8.75% to $782000.0 in 2026.
- Per Business Quant, the three latest RLAY Amortizatization of Intangibles figures stand at $782000.0 (Q1 2026), $857000.0 (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | 782,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 782,000.00 |
| Mar 31, 2026 | 782,000.00 |
| Dec 31, 2025 | 857,000.00 |
| Dec 31, 2025 | 857,000.00 |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | 3.67 Mn |
| Mar 31, 2024 | 3.67 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 385,000.00 |
| Dec 31, 2022 | 385,000.00 |
| Sep 30, 2022 | -340,000.00 |
| Sep 30, 2022 | -340,000.00 |
| Jun 30, 2022 | -546,000.00 |
| Jun 30, 2022 | -546,000.00 |
| Mar 31, 2022 | -681,000.00 |
| Mar 31, 2022 | -681,000.00 |
| Dec 31, 2021 | -681,000.00 |
| Dec 31, 2021 | -681,000.00 |
| Sep 30, 2021 | -670,000.00 |
| Sep 30, 2021 | -670,000.00 |
| Jun 30, 2021 | -548,000.00 |
| Jun 30, 2021 | -548,000.00 |
| Mar 31, 2021 | -153,000.00 |
| Mar 31, 2021 | -153,000.00 |
| Dec 31, 2020 | -14,000.00 |
| Dec 31, 2020 | -14,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | 117,000.00 |
| Jun 30, 2020 | 117,000.00 |
| Mar 31, 2020 | 321,000.00 |
| Mar 31, 2020 | 321,000.00 |
| Dec 31, 2019 | 635,000.00 |
| Dec 31, 2019 | 635,000.00 |
| Sep 30, 2019 | 1.14 Mn |
| Sep 30, 2019 | 1.14 Mn |